U.S. Renal Care in the news

U.S. Renal Care and Satellite Healthcare honored 25 nurses with the DAISY Award for their outstanding clinical care and compassion.

Waystar's Early Adopter Program significantly improved US Renal Care's recoupment management efficiency by reducing time per adjustment and increasing adjustment match rates.

A new report from Peterson Health Technology Institute (PHTI) concludes that virtual chronic kidney disease (CKD) management solutions do not consistently slow disease progression or reduce healthcare costs, a finding that kidney care companies dispute.

U.S. Renal Care is looking to reverse an asset strip from 2023 as part of its new refinancing plan.

U.S. Renal Care has grown its global workforce to approximately 4,458 employees by March 2026, marking a 2.8% increase since 2023.

U.S. Renal Care is expanding access to advanced dialysis therapy, Expanded Hemodialysis, which improves outcomes and quality of life for kidney disease patients.

U.S. Renal Care is planning to unwind a 2023 asset strip maneuver as part of its new refinancing strategy, which will impact lender protections and recovery prospects.

U.S. Renal Care is increasing the availability of advanced medium cut-off dialyzers for hemodialysis patients.

U.S. Renal Care is expanding the availability of advanced MCO dialyzers to improve outcomes and quality of life for hemodialysis patients.

U.S. Renal Care is expanding access to medium cut-off dialyzers for Expanded Hemodialysis, a treatment that improves patient outcomes and quality of life for those with kidney disease.

U.S. Renal Care is expanding the availability of medium cut-off dialyzers to support Expanded Hemodialysis, aiming to improve patient outcomes.

U.S. Renal Care is expanding access to medium cut-off dialyzers for enhanced hemodialysis, improving patient outcomes and quality of life.

US Renal Care, backed by Bain Capital, is offering to return previously stripped assets to lenders as part of a $2 billion refinancing effort.

U.S. Renal Care premiered a short film featuring Dwaine "DJ" Haskins Jr. running the New York City Marathon to raise awareness for kidney disease, inspired by his uncle and other patients.

U.S. Renal Care and Akebia Therapeutics' VOICE trial found Vafseo significantly improved safety outcomes and reduced hospitalizations for kidney disease patients compared to standard treatments, leading to early trial termination.

U.S. Renal Care and Akebia Therapeutics stopped the VOICE trial early due to Vafseo showing significant safety and clinical benefits in reducing mortality and hospitalizations for dialysis patients with CKD-related anemia.

U.S. Renal Care and Akebia Therapeutics halted the VOICE trial due to Vafseo showing significantly improved safety and reduced hospitalizations in dialysis patients with anemia compared to ESAs.

The Vafseo trial, involving U.S. dialysis patients, was stopped early due to improved safety outcomes, meeting superiority criteria for mortality and hospitalization, and showing reduced hospitalizations.

Akebia Therapeutics and U.S. Renal Care stopped their VOICE trial early, as Vafseo significantly improved safety outcomes, particularly by reducing hospitalizations for kidney disease patients on dialysis, compared to standard treatments.

U.S. Renal Care and Akebia Therapeutics halted their VOICE trial early, finding Vafseo significantly improved safety outcomes, particularly reducing hospitalizations, for kidney disease patients compared to standard treatments.